METHODS: A descriptive-analytical cross-sectional study using a researcher-made checklist was conducted on MS patients referred to Neshat Clinic of Hamadan during the years 2020-2021. The checklist contained questions about demographic information, MS phenotype, duration of illness, expanded disability status scale (EDSS) score, and COVID-19 vaccination status. The expanded disability status scale (EDSS) is the most commonly used instrument for measuring disability in patients with multiple sclerosis (MS). The EDSS scale ranges from 0 to 10 in increments of 0.5 units, denoting advanced points of disability.
RESULTS: Based on the results, 20 individuals (10%) were in the vaccine non-acceptance group, while 181 individuals (90%) were in the vaccine acceptance group. A significant number of relapsing and remitting (RR) type MS patients (90.7%) and all primary progressive (PP) type MS patients (100%) accepted the vaccine. In comparison, vaccine non-acceptance in the secondary progressive (SP) group was relatively higher (20.7%) compared to other types of MS, and this difference was significant (P < 0.05). Additionally, there was a statistically significant relationship between the history of COVID-19 and vaccine acceptance (P < 0.05).
CONCLUSIONS: The study results demonstrated a high rate of COVID-19 vaccine acceptance among MS patients. MS phenotype, previous infection experiences, and other influences allow for COVID-19 vaccine acceptance among MS patients. This information can improve health programs and communication strategies for COVID-19 and future possible infectious disease vaccination in individuals with MS.
方法:使用研究人员制作的清单对2020-2021年期间转诊至HamadanNeshat诊所的MS患者进行了描述性分析横断面研究。清单包含有关人口统计信息的问题,MS表型,疾病的持续时间,扩展残疾状况量表(EDSS)评分,和COVID-19疫苗接种状况。扩展残疾状况量表(EDSS)是测量多发性硬化症(MS)患者残疾的最常用工具。EDSS刻度范围从0到10,增量为0.5个单位,表示先进的残疾点。
结果:根据结果,20个人(10%)在疫苗不接受组中,而181名个体(90%)属于疫苗接受组。大量复发和缓解(RR)型MS患者(90.7%)和所有原发性进行性(PP)型MS患者(100%)接受了疫苗。相比之下,与其他类型的MS相比,次级进行性(SP)组的疫苗不接受度相对较高(20.7%),差异有统计学意义(P<0.05)。此外,COVID-19病史与疫苗接受度有统计学意义(P<0.05)。
结论:研究结果表明,MS患者接受COVID-19疫苗的比率很高。MS表型,以前的感染经历,和其他影响因素允许MS患者接受COVID-19疫苗。这些信息可以改善COVID-19的健康计划和沟通策略,以及MS患者未来可能的传染病疫苗接种。